Novartis' generics unit Sandoz initiated a late-stage trial to confirm the biosimilarity of its version of etanercept with Amgen's Enbrel. The international trial will involve the treatment of moderate to severe chronic plaque-type psoriasis. Sandoz intends to use the results to support regulatory filings in the U.S. and Europe.

Full Story:
Reuters, RTT News

Related Summaries